SAB Biotherapeutics (NASDAQ:SABS) Releases Quarterly Earnings Results, Meets Estimates

SAB Biotherapeutics (NASDAQ:SABS) released its earnings results on Thursday. The company reported ($0.28) EPS for the quarter, hitting analysts’ consensus estimates of ($0.28), FiscalAI reports.

Here are the key takeaways from SAB Biotherapeutics’ conference call:

• SAFEGUARD enrollment is accelerating, with more than 60 sites actively recruiting and increased screening and randomization. Management remains on track to complete enrollment in Q4 2026, with top-line data expected in the second half of 2027.
• Breakthrough T1D awarded a grant supporting the PRISE-hATG Phase III study, which is expected to begin enrollment in the second half of 2026 across seven sites. If successful, the study could support a future SAB-142 label expansion for patients treated up to two years after diagnosis, with top-line data expected in Q1 2029.
• SAB Bio ended the quarter with $208 million in cash, cash equivalents, and investments, providing an operating runway through 2028. However, higher clinical-development and headcount costs drove R&D expense to $16.2 million and the net loss to $22.5 million, versus $10.1 million a year earlier.
• Management views the recent FDA approval of Tzield in recently diagnosed Stage 3 Type 1 diabetes as validation that C-peptide can support an accelerated-approval pathway. SAB Bio also highlighted SAB-142’s potential competitive advantages, including two-day dosing and low to no immunogenicity that may enable redosing.

SAB Biotherapeutics Trading Up 1.1%

Shares of SAB Biotherapeutics stock traded up $0.04 on Friday, reaching $3.89. The company had a trading volume of 155,565 shares, compared to its average volume of 680,348. The company has a debt-to-equity ratio of 0.01, a quick ratio of 11.45 and a current ratio of 11.45. The firm has a market cap of $297.58 million, a PE ratio of -1.84 and a beta of 0.53. The firm’s 50 day moving average price is $3.68 and its two-hundred day moving average price is $3.83. SAB Biotherapeutics has a 52-week low of $1.85 and a 52-week high of $5.15.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently made changes to their positions in the business. ADAR1 Capital Management LLC acquired a new position in shares of SAB Biotherapeutics in the third quarter valued at approximately $30,000. Dimensional Fund Advisors LP acquired a new position in shares of SAB Biotherapeutics in the third quarter worth $32,000. State of Wyoming purchased a new stake in shares of SAB Biotherapeutics during the fourth quarter worth $34,000. Virtu Financial LLC acquired a new stake in shares of SAB Biotherapeutics in the third quarter valued at $40,000. Finally, State Street Corp acquired a new stake in shares of SAB Biotherapeutics in the fourth quarter valued at $49,000. Hedge funds and other institutional investors own 7.82% of the company’s stock.

Analyst Ratings Changes

A number of analysts have recently commented on SABS shares. Leerink Partners boosted their price objective on SAB Biotherapeutics from $7.00 to $12.00 and gave the company an “outperform” rating in a research report on Monday, June 15th. Citigroup initiated coverage on shares of SAB Biotherapeutics in a research report on Friday, May 22nd. They set a “buy” rating and a $11.00 price objective for the company. HC Wainwright reissued a “buy” rating and set a $10.00 target price on shares of SAB Biotherapeutics in a research note on Monday, June 15th. Wall Street Zen lowered shares of SAB Biotherapeutics from a “sell” rating to a “strong sell” rating in a research note on Sunday, August 2nd. Finally, Barclays began coverage on SAB Biotherapeutics in a report on Wednesday, June 24th. They issued an “overweight” rating and a $13.00 price objective on the stock. Nine research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, SAB Biotherapeutics presently has a consensus rating of “Moderate Buy” and an average target price of $12.00.

SAB Biotherapeutics Company Profile

SAB Biotherapeutics, Inc is a clinical-stage biotechnology company headquartered in Sioux Falls, South Dakota, that focuses on developing fully human polyclonal antibody therapeutics. The company’s proprietary platform, known as Tc Bovine®, uses genetically engineered cattle to generate large quantities of human antibodies tailored to target specific infectious agents or disease-related antigens. This approach is designed to combine the broad-spectrum coverage of polyclonal antibody therapies with the scalability and consistency required for clinical development and commercial use.

The company’s lead programs are directed primarily at infectious diseases.